Literature DB >> 14666380

Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient.

G Damaj1, V Ivanov, B Le Brigand, E D'incan, M F Doglio, K Bilger, C Faucher, N Vey, J A Gastaut.   

Abstract

A 57-year-old man with acute myeloid leukemia (AML) French-American-British (FAB) 4 developed disseminated invasive cerebral and pulmonary aspergillosis during postinduction aplasia. According to international consensus, infection was categorized as probable (two host factors: deep neutropenia for >10 days and refractory fever for >96 h; major clinical criteria of lower respiratory tract and CNS invasive fungal infection; positive results for galactomannan antigen in three blood samples). After the failure of standard amphotericin-based therapy, the spectacular regression of multifocal brain and lung lesions was rapidly achieved under a caspofungin acetate/voriconazole combination. Further permanent caspofungin maintenance with voriconazole added during aplasia periods permitted two consolidation courses and autograft-based intensification without any delay.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666380     DOI: 10.1007/s00277-003-0792-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis.

Authors:  S Schwartz; A Reisman; P F Troke
Journal:  Infection       Date:  2011-04-22       Impact factor: 3.553

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Guillermo Garcia-Effron; Laura Alcazar-Fuoli; Emilia Mellado; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Cerebral aspergillosis in the critically ill: two cases of successful medical treatment.

Authors:  Stephan Ehrmann; Frédéric Bastides; Valérie Gissot; Emmanuelle Mercier; Pascal Magro; Eric Bailly; Annick Legras
Journal:  Intensive Care Med       Date:  2005-03-22       Impact factor: 17.440

5.  Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis.

Authors:  Yi Sun; Wei Liu; Zhe Wan; Xiaohong Wang; Ruoyu Li
Journal:  Mycopathologia       Date:  2010-08-29       Impact factor: 2.574

Review 6.  CNS aspergillosis: recognition, diagnosis and management.

Authors:  Markus Ruhnke; Grzegorz Kofla; Kirsten Otto; Stefan Schwartz
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole.

Authors:  Víctor López-Ciudad; María J Castro-Orjales; Cristóbal León; César Sanz-Rodríguez; María J de la Torre-Fernández; Miguel A Pérez de Juan-Romero; María D Collell-Llach; María D Díaz-López
Journal:  BMC Infect Dis       Date:  2006-04-11       Impact factor: 3.090

Review 8.  A Systematic Review to Assess the Relationship between Disseminated Cerebral Aspergillosis, Leukemias and Lymphomas, and Their Respective Therapeutics.

Authors:  Brianne N Sullivan; Mia A Baggett; Samantha S O'Connell; Keith M Pickett; Chad Steele
Journal:  J Fungi (Basel)       Date:  2022-07-11

Review 9.  Aspergillosis of central nervous system in patients with leukemia and stem cell transplantation: a systematic review of case reports.

Authors:  Aref Shariati; Mojtaba Didehdar; Shahin Rajaeih; Alireza Moradabadi; Mohammad Ghorbani; Vahid Falahati; Zahra Chegini
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-06-15       Impact factor: 3.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.